德国多发性硬化症患者使用Brisa应用程序收集的关于ocrelizumab治疗的数据
Steffeni Papukchieva1, Maria Kahn1, Markus Eberl1
1Temedica GmbH, 80687 Munich, Germany.
Journal of personalized medicine
|April 27, 2024
概括
像Brisa这样的数字伴侣应用程序为多发性硬化症 (MS) 研究提供了宝贵的实时数据. 这项研究表明,Brisa的用户数据反映了MS患者的现实体验和疾病管理.
科学领域:
- 神经学 神经学
- 数字健康数字健康
- 患者报告的结果
背景情况:
- 多发性硬化症 (MS) 对全球医疗保健系统构成越来越大的挑战.
- 数字伴侣应用程序,如Brisa,正在成为管理MS患者旅程的重要工具.
- 这些应用程序有助于收集关键的实时纵向数据,以了解MS病理生理学和进展.
研究的目的:
- 分析 Brisa 数字健康应用程序的数据,以了解多发性硬化症患者的特征和症状报告.
- 为了比较不同治疗组 (中度疗效,高疗效和ocrelizumab) 的症状报告频率和严重程度.
主要方法:
- 追溯分析2021年8月至2022年9月期间注册的Brisa用户数据.
- 纳入标准需要人口统计和药物信息,以及症状或患者报告结果的跟踪 (1593名用户).
- 用户被分为中度有效治疗用户 (METU),高效治疗用户 (HETU) 和ocrelizumab用户 (OU) 进行比较分析.
主要成果:
- 最大的队列 (405名用户) 使用了ocrelizumab,大多数患者在2-5年前被诊断出来.
- 症状报告频率在ocrelizumab用户 (OU) 中最高.
- 在HETU和OU的基线得分相似,但在METU的基线得分较低. 在OU中,残疾和疼痛得分随着年龄的增长而增加,生活质量,肠道或视力没有与年龄相关的显著差异.
结论:
- 布里萨队列特征与现有的MS研究和注册表一致,提供了日常疾病管理的代表性观点.
- 布里萨数据可以弥合临床研究和真实世界患者体验之间的差距.
- 需要进一步的研究来探索"艰难而早期"的治疗方法以及基线特征如何随着时间的推移影响治疗结果.
更多相关视频
相关概念视频
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...